230 related articles for article (PubMed ID: 1576621)
1. Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
Cuchural GJ; Snydman DR; McDermott L; Iannini PB; Hill GB; Cleary TJ; O'Keefe JP; Pierson CL; Rihs JD; Finegold SM
Clin Ther; 1992; 14(1):122-36. PubMed ID: 1576621
[TBL] [Abstract][Full Text] [Related]
2. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
3. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
[TBL] [Abstract][Full Text] [Related]
4. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
[TBL] [Abstract][Full Text] [Related]
6. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.
Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Gorbach SL
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S126-34. PubMed ID: 12173121
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
8. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
Downes J; Andrew JH
Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.
Dornbusch K; Nord CE; Olsson-Liljeqvist B
Scand J Infect Dis Suppl; 1979; (19):17-25. PubMed ID: 37593
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
Martín MA; Castillo AM; Liébana J; Marín A; Alados JC; Piédrola G
J Hyg Epidemiol Microbiol Immunol; 1991; 35(2):189-97. PubMed ID: 1940333
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
[TBL] [Abstract][Full Text] [Related]
13. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
Aldridge KE; Henderberg A; Sanders CV
J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of antimicrobial resistance patterns of enterotoxin gene positive and negative Bacteroides fragilis isolates].
Toprak NU; Yağci A; Celik C; Cakici O; Söyletir G
Mikrobiyol Bul; 2005 Apr; 39(2):145-52. PubMed ID: 16128024
[TBL] [Abstract][Full Text] [Related]
15. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
[TBL] [Abstract][Full Text] [Related]
16. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
Snydman DR; McDermott L; Cuchural GJ; Hecht DW; Iannini PB; Harrell LJ; Jenkins SG; O'Keefe JP; Pierson CL; Rihs JD; Yu VL; Finegold SM; Gorbach SL
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S54-65. PubMed ID: 8953108
[TBL] [Abstract][Full Text] [Related]
17. [ESBL-positive strains of the Bacteroides fragilis group isolated from patients at the regional hospital center in Płock (Poland)].
Rokosz A; Pawłowska J; Sawicka-Grzelak A; Luczak M
Med Dosw Mikrobiol; 2004; 56(3):245-53. PubMed ID: 15773501
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic resistance among anaerobic Gram-negative bacilli: lessons from a French multicentric survey.
Behra-Miellet J; Calvet L; Mory F; Muller C; Chomarat M; Bézian MC; Bland S; Juvenin ME; Fosse T; Goldstein F; Jaulhac B; Dubreuil L
Anaerobe; 2003 Jun; 9(3):105-11. PubMed ID: 16887696
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
Gill CJ; Ponticas S; Shungu DL; Guerriero S
Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
[TBL] [Abstract][Full Text] [Related]
20. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
